International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing-Reference-Cited by-同舟云学术

International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing

Published:2016-09-07 Issue:12 Volume:56 Page:2964-2972
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Chapuy Claudia I.¹,Aguad Maria D.²,Nicholson Rachel T.³,AuBuchon James P.⁴^ORCID,Cohn Claudia S.⁵,Delaney Meghan⁶,Fung Mark K.⁷,Unger Meredith⁸,Doshi Parul⁹,Murphy Michael F.¹⁰,Dumont Larry J.¹¹¹²,Kaufman Richard M.²,

Affiliation:

1. Dana-Farber Cancer Institute at St Elizabeth's Medical Center; Boston Massachusetts

2. Brigham and Women's Hospital; Boston Massachusetts

3. Massachusetts General Hospital; Boston Massachusetts

4. Bloodworks Northwest; Seattle Washington

5. University of Minnesota; Minneapolis Minnesota

6. Bloodworks Northwest, Seattle Children's Hospital, University of Washington; Seattle Washington

7. University of Vermont Medical Center; Burlington Vermont

8. Janssen, Inc; Raritan New Jersey

9. Janssen Research & Development; Springhouse Pennsylvania

10. NHS Blood and Transplant; Oxford United Kingdom

11. Dartmouth-Hitchcock Medical Center; Lebanon New Hampshire

12. Dartmouth-Hitchcock Medical Center; Hanover New Hampshire

Funder

Janssen, Inc.

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.13789/fullpdf

Reference15 articles.

1. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;Weers;J Immunol,2011

2. Targeting CD38 with daratumumab monotherapy in multiple myeloma;Lokhorst;N Engl J Med,2015

3. 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036s000lbl.pdf

4. Daratumumab: first global approval;McKeage;Drugs,2016

5. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial;Lonial;Lancet,2016

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Valutazione di un metodo commerciale basato sull'utilizzo del CD38 solubile per mitigare l'interferenza del daratumumab sui test pre-trasfusionali;La Rivista Italiana della Medicina di Laboratorio;2024-09

2. Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment;Biomedicines;2024-07-24

3. Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab;Journal of Clinical Medicine;2024-07-14

4. Interference of Monoclonal Antibody Therapy in Transfusion: An Update;Hemato;2024-07-02

5. Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?;Vox Sanguinis;2024-05-05